Matthew Peterson
Hematology & Oncology · Uvalde, TXNPI 1730475351
Payments from drug & device makers
Across 225 payments — averaging $558.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$52K
- Seagen Inc.$30K
- E.r. Squibb & Sons, L.L.C.$22K
- Regeneron$17K
- AstraZeneca$474
- Novartis$419
- plus $3K from 38 others
What the payments were for
- Food & beverage$4,18098%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPOVIO$117
How this compares
$125,632 in reported general payments places this provider in the 70th percentile of 838 hematology & oncology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 36 | $505,145 |
| JakafiRuxolitinib Phosphate | 18 | $330,380 |
| VonjoPacritinib Citrate | 11 | $290,390 |
| SprycelDasatinib | 13 | $212,005 |
| Abiraterone Acetate | 35 | $178,576 |
| IbrancePalbociclib | 11 | $167,460 |
| VerzenioAbemaciclib | 11 | $105,587 |
| EliquisApixaban | 25 | $33,887 |
| OrgovyxRelugolix | 13 | $33,159 |
| XareltoRivaroxaban | 19 | $14,954 |
| Anastrozole | 95 | $1,999 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 46 | $1,776 |
| Exemestane | 12 | $1,393 |
| Ondansetron OdtOndansetron | 65 | $892 |
| Fentanyl | 13 | $877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $115 | $505,14536 claims |
| Incyte CorporationJakafi | $225 | $330,38018 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $22,445 | $212,00513 claims |
| PfizerIbrance, Eliquis | $125 | $201,34636 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $122 | $105,95267 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $29 | $33,15913 claims |
| Johnson & JohnsonXarelto | $333 | $14,95419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Uvalde
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Kyriakos PapadopoulosSan Antonio$18.5M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
- Drew RascoSan Antonio$14.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.